biosimilar limited use in some health systems for biosimilars are not well understood by many health professionals and patients. This knowledge gap is exacerbated by
Objective: This study aimed to analyze the cost-effectiveness and biosimilar infliximab compared with conventional therapy in fireproof moderate to severe Crohn’s disease (CD) in Thailand.Materials